Ten choices on capital, use cases, people, IP and governance that determine whether AI creates measurable advantage in Pharma, not just measurable activity.
Ten CEO-level questions, from capital allocation to workforce redesign to governance.
5%
Only 5% of surveyed life-sciences organizations describe gen AI as a consistent competitive differentiator, despite universal experimentation.
McKinsey, 2025 · cited in the guideSeven guides, from the CEO agenda to the plant floor. Each is a ranked, sourced priority sequence, built on research from Bain, McKinsey, Deloitte, BCG, EY, ZS and MIT NANDA.
Ten decisions. One download. Free, no spam, no sales pitch first.
Backed by Bain, McKinsey, Deloitte, BCG and EY research
The guide is on its way to your inbox.